Figure 1 (Herzuma 01)
Herzuma Kit
Product Images NDC 63459-305
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Herzuma (NDC 63459-305). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Cephalon, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 2 (Herzuma 02)
This appears to be a graph showing cumulative incidence rates over time, with time measured in months. The y-axis displays incidence rate percentages ranging from 0%-50%. The x-axis shows the time in months, with the time from randomization. It also includes a chart of "Number at Risk" with the corresponding time points, but the data is not clear due to errors in the .*
Figure 3 (Herzuma 03)
Figure 4 (Herzuma 04)
Figure 5 (Herzuma 05)
Principal Display Panel (Kit Carton Label)
Herzuma 07
This is a graph that shows the survival probability of patients with different treatments over a period of months. The survival probabilities are presented as product-limit survival estimates with the number of subjects at risk. The graph compares the Fluoropyrimidine + Gisplatin treatment with Fluoropyrimicine + Cisplati + Trastuzumab treatment. The duration of survival is measured in months.*
Herzuma 08
This is a prescription multiple-use vial of Herzumar, containing 420mg of trastuzumab-pkrb for intravenous infusion only. No preservatives are included, and the drug must be kept refrigerated. Reconstitution and dilution are required as per the instructions provided. The drug is manufactured by Teva.*
Herzuma 09
The text provides information on a medication called "Herzumar" with the active ingredient "trastuzumab-pkrb". The medication is only available via prescription and comes in a single-dose vial containing 150 mg. The medication must be diluted and administered via intravenous infusion only. The unused portion of the medication should be discarded, and the medication does not contain any preservatives. The medication should be kept refrigerated.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
